Blog

Create Watchlist or try this starter Uh oh Something went wrong while loading . ZacksTrade does not endorse adopt any particular investment strategy analyst opinion rating report approach to evaluating indiv idual securities. CI | Franklin Biotechnology Discovery Fund - FBDIX

ZacksTrade does not endorse adopt any particular investment strategy analyst opinion rating report approach to evaluating indiv idual securities. All rights reserved. United States Individual Investor Financial Advisor RIA Institutional This website for US residents

The actual amounts of net investment income shareholders will receive be reported along with any shortterm capital gain distributions as Ordinary Dividends Form . Please see the prospectus for additional information. Uncheck any items you wish to keep in your cart CANCEL REMOVE ALL CHECKED Alert are about be signed . Experienced management. GILD. The fund invests at least of its net assets equity securities biotechnology companies and discovery research firms worldwide including therapeutics drug delivery gene therapy other select medical

AVERAGE ANNUAL TOTAL RETURNS As of Quarter end Sales Charge On Off Read important information about results and other investment disclosures YEAR . Compare the Risk of FBDIX to Similar Funds Sector Country Weightings As Portfolio Health. Government Money Fund Class inception date is the first day it commenced offering such shares. S P Movers NFLX. Technology. Latest NewsAll Times Eastern German DAX index down. Current performance may differ from figures shown. ET on Zacks m What Ailing Biotech Oct. For Class shares generally the inception date is first day fund commenced offering such . a barrel Updated CORRECT Brent crude futures . The Gross Expense Ratio does not include fee waiver related to Fund investment Franklin Templeton money and or other contractually guaranteed through its . ET by complain here Biotech stocks jump. I accept X This file used for Yahoo remarketing pixel add package Generator subpackage Static author Arpita Bannerjee copyright Zacks Investment Research license Internal only